Products

Porphyromonas endodontalis cDNA and Antigen

Cat#

Product Name

Swiss Prot#

Size

Price (US$)

Order

PP0684

Recombinant Protein-Porphyromonas endodontalis Immunoreactive 47 kD antigen (a.a.61 to 429)

C3J899

100 µg

1195

Order

PP0685

Recombinant Protein-Porphyromonas endodontalis Immunoreactive 47 kDa antigen PG97 (a.a.31 to 532)

C3JB10

100 µg

1195

Order

PP0686

Recombinant Protein-Porphyromonas endodontalis Immunoreactive 84 kDa antigen PG93 (a.a.61 to 460)

C3J7V5

100 µg

1195

Order

PP0687

Recombinant Protein-Porphyromonas endodontalis immunoreactive 47 kDa antigen PG97 (a.a.26 to 376)

C3J9P5

100 µg

1195

Order

PP0688

Recombinant Protein-Porphyromonas endodontalis surface antigen BspA (a.a.61 to 468)

C3JCN1

100 µg

1195

Order

PP0689

Recombinant Protein-Porphyromonas endodontalis Receptor antigen (a.a.61 to 460)

C3J7P6

100 µg

1195

Order

PP0690

Recombinant Protein-Porphyromonas endodontalis 60 kDa chaperonin (a.a.61 to 548)

C3J7X5

100 µg

1195

Order

RPP0684

cDNA-Porphyromonas endodontalis Immunoreactive 47 kD antigen (a.a.61 to 429)

C3J899

2 µg

1840

Order

RPP0685

cDNA-Porphyromonas endodontalis Immunoreactive 47 kDa antigen PG97 (a.a.31 to 532)

C3JB10

2 µg

2505

Order

RPP0686

cDNA-Porphyromonas endodontalis Immunoreactive 84 kDa antigen PG93 (a.a.61 to 460)

C3J7V5

2 µg

1995

Order

RPP0687

cDNA-Porphyromonas endodontalis immunoreactive 47 kDa antigen PG97 (a.a.26 to 376)

C3J9P5

2 µg

1750

Order

RPP0688

cDNA-Porphyromonas endodontalis surface antigen BspA (a.a.61 to 468)

C3JCN1

2 µg

2035

Order

RPP0689

cDNA-Porphyromonas endodontalis Receptor antigen (a.a.61 to 460)

C3J7P6

2 µg

1995

Order

RPP0690

cDNA-Porphyromonas endodontalis 60 kDa chaperonin (a.a.61 to 548)

C3J7X5

2 µg

2435

Order

Porphyromonas endodontalis cDNA and recombinant antigen

  • Codon-optimized cDNA is cloned into E. coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
  • Recombinant protein applications: Western Blot may be used for other applications determined by the user.
  • Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions.
  • Protein Activity: N/A
  • Protein Tag:  Contains A 6x histidine tag at N-terminus.
  • Protein Formulation: Liquid
  • Source: Produced from E. coli

Porphyromonas endodontalisis a gram-negative anaerobic bacterium that is commonly found in infected root canals of teeth. The bacterium possesses several immunoreactive antigens on its surface that are involved in the pathogenesis of endodontic infections. In this article, we will discuss several of these immunoreactive antigens, including the 47 kD antigen, 84 kDa antigen, BspA surface antigen, receptor antigen, and the chaperonin 60 kDa.

47 kD Antigen
The 47 kD antigen is a major immunoreactive protein of Porphyromonas endodontalis that is involved in the pathogenesis of endodontic infections. This antigen has been shown to induce immune responses in the host, and it is considered a potential vaccine candidate. Further studies are needed to determine the role of this protein in the pathogenesis of endodontic infections.

84 kDa Antigen
The 84 kDa antigen is another immunoreactive protein of Porphyromonas endodontalis that has been shown to play a role in the pathogenesis of endodontic infections. This antigen has been identified as a potential target for developing diagnostic tests and vaccines.

BspA Surface Antigen
BspA is a surface antigen of Porphyromonas endodontalis that is involved in bacterial adhesion to host tissues. This antigen has been shown to be important in the pathogenesis of endodontic infections and has been identified as a potential therapeutic target.

Receptor Antigen
The receptor antigen of Porphyromonas endodontalis is involved in the binding of the bacterium to host cells. This antigen has been shown to play a role in the pathogenesis of endodontic infections and has been identified as a potential therapeutic target.

Chaperonin 60 kDa
The chaperonin 60 kDa of Porphyromonas endodontalis is a heat shock protein that has been shown to be involved in the virulence of the bacterium. This protein has been identified as a potential therapeutic target for treating endodontic infections.

Porphyromonas endodontalis possesses several immunoreactive antigens that are involved in the pathogenesis of endodontic infections. These antigens have significant potential in vaccine development and the control of bacterial infections. Further studies are needed to fully explore the potential of these antigens and their mechanisms of action in the pathogenesis of endodontic infections.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA (complementary DNA) and recombinant antigen of P. endodontalis can be used in various applications for diagnosis, research, and vaccine development.

Diagnostic Tests: cDNA of P. endodontalis can be used in molecular diagnostic tests to detect the presence of the bacterium in a patient’s sample. This can be done by amplifying a specific genetic target using polymerase chain reaction (PCR) and detecting the amplified product using fluorescence or other methods.

Research: cDNA of P. endodontalis can be used in research studies to investigate the genetic characteristics and pathogenesis of the bacterium. Recombinant antigens can also be used to study the immune response to P. endodontalis infections, to identify potential vaccine candidates, and to develop new diagnostic tests.

Vaccine Development: Recombinant antigens of P. endodontalis can be used to develop vaccines against the bacterium. These vaccines can stimulate the production of specific antibodies that recognize and neutralize P. endodontalis.

 

Welcome to BitClone

Magnetic Beads Make Things Simple